Brief: Travere Therapeutics Announces Full FDA Approval Of Filspari®
05/09/2024 22:35
Sept 5 (Reuters) - Travere Therapeutics Inc TVTX.O :
* TRAVERE THERAPEUTICS ANNOUNCES FULL FDA APPROVAL OF
FILSPARI®
(SPARSENTAN), THE ONLY NON-IMMUNOSUPPRESSIVE TREATMENT THAT
SIGNIFICANTLY SLOWS KIDNEY FUNCTION DECLINE IN IGA NEPHROPATHY
* TRAVERE THERAPEUTICS INC - FILSPARI WELL TOLERATED WITH
CLEARLY
DEFINED SAFETY PROFILE
Source text for Eikon: ID:nGNX5pnhH0
Further company coverage: TVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule